| Trial ID: | L6555 |
| Source ID: | NCT01606371
|
| Associated Drug: |
Placebo
|
| Title: |
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: LY2409021
|
| Outcome Measures: |
Primary: Number of participants with one or more drug related adverse events (AEs) or any serious AEs, From first dose of study drug up to discharge (at least 14 days after last dose) | Secondary: Pharmacokinetics: Area under the concentration curve (AUC) of LY2409021, From each dose of study drug up to 14 days post dose|Pharmacokinetics: Maximum concentration (Cmax) of LY2409021, From each dose of study drug up to 14 days post dose|Change in fasting blood glucose level, From each dose of study drug up to 48 hours post dose|Change in fasting insulin level, From each dose of study drug up to 48 hours post dose|Change in fasting glucagon level, From each dose of study drug up to 48 hours post dose|Change in fasting glucagon-like peptide-1 (GLP-1) level, From each dose of study drug up to 24 hours post dose|Glucose excursion after meals, 28 hours after each dose
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2007-05
|
| Completion Date: |
2007-10
|
| Results First Posted: |
|
| Last Update Posted: |
2012-05-25
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
|
| URL: |
https://clinicaltrials.gov/show/NCT01606371
|
